{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T09:56:38Z","timestamp":1789466198683,"version":"build-2803163510"},"reference-count":71,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2017,1,1]],"date-time":"2017-01-01T00:00:00Z","timestamp":1483228800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,1,1]],"date-time":"2017-01-01T00:00:00Z","timestamp":1483228800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,11,16]],"date-time":"2020-11-16T00:00:00Z","timestamp":1605484800000},"content-version":"vor","delay-in-days":1415,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["esmoopen.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Open"],"published-print":{"date-parts":[[2017]]},"DOI":"10.1136\/esmoopen-2017-000165","type":"journal-article","created":{"date-parts":[[2017,6,23]],"date-time":"2017-06-23T20:20:20Z","timestamp":1498249220000},"page":"e000165","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"title":["Checkpoint inhibitors in the treatment of urological malignancies"],"prefix":"10.1016","volume":"2","author":[{"given":"Lazar S.","family":"Popovic","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gorana","family":"Matovina-Brko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maja","family":"Popovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1136\/esmoopen-2017-000165_bb0010","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/S0022-5347(17)58737-6","article-title":"Intracavitary Bacillus Calmette-Guerin in the treatment of superficial bladder tumors","volume":"116","author":"Morales","year":"1976","journal-title":"J Urol"},{"key":"10.1136\/esmoopen-2017-000165_bb0015","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1200\/JCO.1995.13.3.688","article-title":"Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy","volume":"13","author":"Fyfe","year":"1995","journal-title":"J Clin Oncol"},{"key":"10.1136\/esmoopen-2017-000165_bb0020","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1056\/NEJM199804303381805","article-title":"Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. Groupe Fran\u00e7ais D'immunoth\u00e9rapie","volume":"338","author":"Negrier","year":"1998","journal-title":"N Engl J Med"},{"key":"10.1136\/esmoopen-2017-000165_bb0025","first-page":"CD001425","article-title":"Immunotherapy for advanced renal cell Cancer","volume":"1","author":"Coppin","year":"2005","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1136\/esmoopen-2017-000165_bb0030","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1158\/1078-0432.CCR-14-1520","article-title":"The high-dose aldesleukin \"select\" trial: a trial to prospectively validate predictive models of response to treatment in patients with metastatic renal cell carcinoma","volume":"21","author":"McDermott","year":"2015","journal-title":"Clin Cancer Res"},{"key":"10.1136\/esmoopen-2017-000165_bb0035","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1200\/JCO.2002.20.1.289","article-title":"Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma","volume":"20","author":"Motzer","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1136\/esmoopen-2017-000165_bb0040","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1056\/NEJMoa1001294","article-title":"Sipuleucel-T immunotherapy for castration-resistant prostate Cancer","volume":"363","author":"Kantoff","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1136\/esmoopen-2017-000165_bb0045","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1136\/esmoopen-2017-000165_bb0050","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1056\/NEJMoa1503093","article-title":"Pembrolizumab versus Ipilimumab in Advanced Melanoma","volume":"372","author":"Robert","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1136\/esmoopen-2017-000165_bb0055","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1056\/NEJMoa1414428","article-title":"Nivolumab and ipilimumab versus ipilimumab in untreated melanoma","volume":"372","author":"Postow","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1136\/esmoopen-2017-000165_bb0060","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1056\/NEJMoa1507643","article-title":"Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell lung Cancer","volume":"373","author":"Borghaei","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1136\/esmoopen-2017-000165_bb0065","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","article-title":"Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell lung Cancer","volume":"375","author":"Reck","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1136\/esmoopen-2017-000165_bb0070","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(16)32517-X","article-title":"Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung Cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial","volume":"389","author":"Rittmeyer","year":"2017","journal-title":"Lancet"},{"key":"10.1136\/esmoopen-2017-000165_bb0075","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1411087","article-title":"PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma","volume":"372","author":"Ansell","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1136\/esmoopen-2017-000165_bb0080","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/S1470-2045(16)30066-3","article-title":"Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial","volume":"17","author":"Seiwert","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1136\/esmoopen-2017-000165_bb0085","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1056\/NEJMoa1510665","article-title":"Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma","volume":"373","author":"Motzer","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1136\/esmoopen-2017-000165_bb0090","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1016\/S0140-6736(16)00561-4","article-title":"Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial","volume":"387","author":"Rosenberg","year":"2016","journal-title":"Lancet"},{"key":"10.1136\/esmoopen-2017-000165_bb0095","first-page":"1","article-title":"Mellman I Oncology meets immunology: the cancer-immunity cycle immunity","volume":"39","author":"Chen","year":"2013"},{"key":"10.1136\/esmoopen-2017-000165_bb0100","doi-asserted-by":"crossref","first-page":"1974","DOI":"10.1200\/JCO.2014.59.4358","article-title":"Immune checkpoint blockade in Cancer therapy","volume":"33","author":"Postow","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1136\/esmoopen-2017-000165_bb0105","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1093\/intimm\/dxu076","article-title":"Therapeutic use of anti-CTLA-4 antibodies","volume":"27","author":"Blank","year":"2015","journal-title":"Int Immunol"},{"key":"10.1136\/esmoopen-2017-000165_bb0110","unstructured":"ClinicalTrials.gov Identifier. NCT02662062 Pembrolizumab with Chemoradiotherapy as treatment for Muscle Invasive Bladder Cancer."},{"key":"10.1136\/esmoopen-2017-000165_bb0115","unstructured":"ClinicalTrials.gov Identifier. NCT02808143 A phase 1 Dose-Escalation Study of intravesical MK-3475 and Bacillus Calmette-Guerin (BCG) in subjects with high risk and BCG-Refractory Non-Muscle Invasive Bladder Cancer."},{"key":"10.1136\/esmoopen-2017-000165_bb0120","unstructured":"ClinicalTrials.gov Identifier:. NCT02787005 phase II trial ofPembrolizumab (MK-3475) in subjects with metastatic Castration-Resistant prostate Cancer (mCRPC) Previously treated with chemotherapy (KEYNOTE-199)."},{"key":"10.1136\/esmoopen-2017-000165_bb0125","unstructured":"ClinicalTrials.gov Identifier:. NCT02853344 A phase II Single-arm, Open-label Monotherapy clinical trial ofPembrolizumab (MK-3475) in locally Advanced\/Metastatic Renal-cell carcinoma (mRCC) (KEYNOTE-427)."},{"key":"10.1136\/esmoopen-2017-000165_bb0130","doi-asserted-by":"crossref","first-page":"e275","DOI":"10.1016\/S1470-2045(16)30242-X","article-title":"Anti-PD-L1 inhibitor durvalumab in bladder cancer","volume":"17","author":"Brower","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1136\/esmoopen-2017-000165_bb0135","doi-asserted-by":"crossref","DOI":"10.1038\/cr.2016.102","article-title":"Structural basis of anti-PD-L1 monoclonal antibody avelumab for tumor therapy","volume":"27","author":"Liu","year":"2017","journal-title":"Cell Res"},{"issue":"Suppl 3","key":"10.1136\/esmoopen-2017-000165_bb0140","doi-asserted-by":"crossref","first-page":"iii40","DOI":"10.1093\/annonc\/mdu223","article-title":"Bladder cancer: ESMO Practice Guidelines for diagnosis, treatment and follow-up","volume":"25","author":"Bellmunt","year":"2014","journal-title":"Ann Oncol"},{"key":"10.1136\/esmoopen-2017-000165_bb0145","doi-asserted-by":"crossref","first-page":"4602","DOI":"10.1200\/JCO.2005.07.757","article-title":"Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder Cancer","volume":"23","author":"von der Maase","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1136\/esmoopen-2017-000165_bb0150","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1200\/JCO.2011.37.3571","article-title":"Randomized phase II\/III trial assessing gemcitabine\/carboplatin and methotrexate\/carboplatin\/vinblastine in patients with advanced urothelial Cancer who are unfit for cisplatin-based chemotherapy: eortc study 30986","volume":"30","author":"De Santis","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1136\/esmoopen-2017-000165_bb0155","doi-asserted-by":"crossref","first-page":"4454","DOI":"10.1200\/JCO.2008.20.5534","article-title":"Phase III trial of vinflunine plus best supportive care compared with best supportive care alone after a platinum-containing regimen in patients with advanced transitional cell carcinoma of the urothelial tract","volume":"27","author":"Bellmunt","year":"2009","journal-title":"J Clin Oncol"},{"issue":"suppl; abstr 4501","key":"10.1136\/esmoopen-2017-000165_bb0160","article-title":"A phase ia study of MPDL3280A (anti-PDL1): Updated response and survival data in urothelial bladder Cancer (UBC)","volume":"33","author":"Petrylak","year":"2015","journal-title":"J Clin Oncol"},{"issue":"18_suppl","key":"10.1136\/esmoopen-2017-000165_bb0165","doi-asserted-by":"crossref","first-page":"LBA4500","DOI":"10.1200\/JCO.2016.34.18_suppl.LBA4500","article-title":"Atezolizumab (atezo) as first-line (1L) therapy in cisplatin-ineligible locally advanced\/metastatic urothelial carcinoma (mUC): Primary analysis of IMvigor210 cohort 1","volume":"34","author":"Balar","year":"2016","journal-title":"Journal of Clinical Oncology"},{"key":"10.1136\/esmoopen-2017-000165_bb0170","unstructured":"ClinicalTrials.gov Identifier:. NCT02302807 A phase III, Open-Label, Multicenter, Randomized Study to investigate the Efficacy and Safety of Atezolizumab (Anti-PD-L1 antibody) Compared with chemotherapy in patients with locally Advanced or metastatic urothelial bladder Cancer after failure with Platinum-Containing chemotherapy."},{"key":"10.1136\/esmoopen-2017-000165_bb0175","unstructured":"ClinicalTrials.gov Identifier. NCT02807636 A phase III, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study of Atezolizumab (Anti PD-L1 antibody) in combination with Gemcitabine\/Carboplatin Versus Gemcitabine\/Carboplatin alone in patients with untreated locally Advanced or metastatic urothelial carcinoma who are ineligible for Cisplatin-Based therapy (IMvigor130) ."},{"key":"10.1136\/esmoopen-2017-000165_bb0180","unstructured":"ClinicalTrials.gov Identifier:. NCT02450331 A phase III, Open-Label, Multicenter, Randomized Study of Atezolizumab (Anti-PD-L1 antibody) Versus Observation as adjuvant therapy in patients with PD-L1-Selected, High-Risk Muscle-Invasive bladder Cancer after Cystectomy."},{"issue":"suppl; abstr 4502","key":"10.1136\/esmoopen-2017-000165_bb0185","article-title":"Pembrolizumab (MK-3475) for advanced urothelial Cancer: updated results and biomarker analysis from KEYNOTE-012","volume":"33","author":"Plimack","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1136\/esmoopen-2017-000165_bb0190","series-title":"Keynote-045: open-label, phase III study of pembrolizumab versus investigator\u2019s choice of paclitaxel, docetaxel, or vinflunine for previously treated advanced urothelial cancer","author":"Bellmunt","year":"2016"},{"key":"10.1136\/esmoopen-2017-000165_bb0195","doi-asserted-by":"crossref","first-page":"A32","DOI":"10.1093\/annonc\/mdw435.25","article-title":"Pembrolizumab (pembro) as first-line therapy for advanced\/unresectable or metastatic urothelial Cancer: preliminary results from the phase 2 KEYNOTE-052 study","volume":"27","author":"Balar","year":"2016","journal-title":"Annals of Oncology"},{"key":"10.1136\/esmoopen-2017-000165_bb0200","unstructured":"ClinicalTrials.gov Identifier:. NCT02853305 A phase III Randomized, Controlled clinical trial of Pembrolizumab with or without Platinum-Based Combination Chemotherapy Versus Chemotherapy in Subjects with Advanced or metastatic urothelial carcinoma."},{"key":"10.1136\/esmoopen-2017-000165_bb0205","unstructured":"ClinicalTrials.gov Identifier:. NCT02625961 A phase II clinical trial to Study the Efficacy and Safety of Pembrolizumab (MK-3475) in subjects with high risk Non-muscle invasive bladder Cancer (NMIBC) Unresponsive to Bacillus Calmette-Guerin (BCG) Therapy."},{"key":"10.1136\/esmoopen-2017-000165_bb0210","doi-asserted-by":"crossref","first-page":"3119","DOI":"10.1200\/JCO.2016.67.9761","article-title":"Safety and efficacy of Durvalumab (MEDI4736), an Anti-Programmed cell death Ligand-1 Immune Checkpoint Inhibitor, in patients with Advanced Urothelial Bladder Cancer","volume":"34","author":"Massard","year":"2016","journal-title":"J Clin Oncol"},{"issue":"suppl; abstr 4501","key":"10.1136\/esmoopen-2017-000165_bb0215","article-title":"Efficacy and safety of nivolumab monotherapy in metastatic urothelial Cancer (mUC): Results from the phase I\/II CheckMate 032 study","volume":"34","author":"Sharma","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1136\/esmoopen-2017-000165_bb0220","first-page":"A31","article-title":"Efficacy and safety of nivolumab monotherapy in patients with metastatic urothelial Cancer (mUC) who have recieved previous treatment: results from the phase II CheckMate 275 study ESMO","volume":"LB","author":"Galsky","year":"2016","journal-title":"J Clin Oncol"},{"issue":"7492","key":"10.1136\/esmoopen-2017-000165_bb0225","first-page":"315","volume":"507","author":"Cancer Genome Atlas Research Network Comprehensive molecular characterization of urothelial bladder carcinoma Nature","year":"2014"},{"issue":"suppl; abstr 4514","key":"10.1136\/esmoopen-2017-000165_bb0230","article-title":"Avelumab (MSB0010718C; anti-PD-L1) in patients with metastatic urothelial carcinoma from the JAVELIN solid tumor phase 1b trial: analysis of safety, clinical activity, and PD-L1 expression","volume":"34","author":"Apolo","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1136\/esmoopen-2017-000165_bb0235","unstructured":"ClinicalTrials.gov Identifier:. NCT02516241 A phase III, Randomized, Open-Label, Controlled, Multi-Center, Global Study of First-Line MEDI4736 Monotherapy and MEDI4736 in Combination with Tremelimumab Versus Standard of Care Chemotherapy in Patients with Unresectable Stage IV Urothelial Cancer ."},{"key":"10.1136\/esmoopen-2017-000165_bb0240","unstructured":"ClinicalTrials.gov Identifier:. NCT02603432 A phase 3, Multicenter, Multinational, Randomized, Open-label, Parallel-arm Study of Avelumab (msb0010718c) Plus best supportive care Versus best supportive care alone as A Maintenance treatment in patients with locally Advanced or metastatic urothelial Cancer whose disease did not Progress after Completion of First-line Platinum-containing chemotherapy."},{"key":"10.1136\/esmoopen-2017-000165_bb0245","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1056\/NEJMoa065044","article-title":"Sunitinib versus interferon alfa in metastatic renal-cell carcinoma","volume":"356","author":"Motzer","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1136\/esmoopen-2017-000165_bb0250","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1056\/NEJMoa1303989","article-title":"Pazopanib versus sunitinib in metastatic renal-cell carcinoma","volume":"369","author":"Motzer","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1136\/esmoopen-2017-000165_bb0255","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1097\/CJI.0b013e318156e47e","article-title":"Ipilimumab (anti-CTLA4 antibody) causes regression of metastatic renal cell Cancer associated with enteritis and hypophysitis","volume":"30","author":"Yang","year":"2007","journal-title":"J Immunother"},{"key":"10.1136\/esmoopen-2017-000165_bb0260","doi-asserted-by":"crossref","first-page":"3167","DOI":"10.1200\/JCO.2009.26.7609","article-title":"Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates","volume":"28","author":"Brahmer","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1136\/esmoopen-2017-000165_bb0265","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","article-title":"Safety, activity, and immune correlates of anti-PD-1 antibody in Cancer","volume":"366","author":"Topalian","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1136\/esmoopen-2017-000165_bb0270","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1200\/JCO.2014.59.0703","article-title":"Nivolumab for metastatic renal cell carcinoma: results of a Randomized phase II trial","volume":"33","author":"Motzer","year":"2015","journal-title":"J Clin Oncol"},{"issue":"2_suppl","key":"10.1136\/esmoopen-2017-000165_bb0275","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1200\/jco.2016.34.2_suppl.498","article-title":"CheckMate 025 phase III trial: Outcomes by key baseline factors and prior therapy for nivolumab (NIVO) versus everolimus (EVE) in advanced renal cell carcinoma (RCC)","volume":"34","author":"Motzer","year":"2016","journal-title":"Journal of Clinical Oncology"},{"key":"10.1136\/esmoopen-2017-000165_bb0280","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1056\/NEJMoa1200694","article-title":"Safety and activity of anti-PD-L1 antibody in patients with advanced Cancer","volume":"366","author":"Brahmer","year":"2012","journal-title":"N Engl J Med"},{"issue":"suppl; abstr 4505","key":"10.1136\/esmoopen-2017-000165_bb0285","article-title":"Clinical activity, safety, and biomarkers of MPDL3280A, an engineered PD-L1 antibody in patients with metastatic renal cell carcinoma (mRCC)","author":"Cho","year":"2013","journal-title":"J Clin Oncol 31"},{"key":"10.1136\/esmoopen-2017-000165_bb0290","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1200\/JCO.2015.63.7421","article-title":"Atezolizumab, an Anti-Programmed Death-Ligand 1 antibody, in metastatic renal cell carcinoma: long-term Safety, clinical activity, and immune correlates from a phase Ia study","volume":"34","author":"McDermott","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1136\/esmoopen-2017-000165_bb0295","doi-asserted-by":"crossref","first-page":"333","DOI":"10.7150\/jca.2.333","article-title":"Immunological effects of multikinase inhibitors for kidney Cancer: a clue for integration with cellular therapies?","volume":"2","author":"Porta","year":"2011","journal-title":"J Cancer"},{"key":"10.1136\/esmoopen-2017-000165_bb0300","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1038\/nrc3237","article-title":"Combining immunotherapy and targeted therapies in Cancer treatment","volume":"12","author":"Vanneman","year":"2012","journal-title":"Nat Rev Cancer"},{"key":"10.1136\/esmoopen-2017-000165_bb0305","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1002\/cncr.25639","article-title":"Phase 1 dose-escalation trial of tremelimumab plus sunitinib in patients with metastatic renal cell carcinoma","volume":"117","author":"Rini","year":"2011","journal-title":"Cancer"},{"issue":"5ssuppl; abstr 5010","key":"10.1136\/esmoopen-2017-000165_bb0310","article-title":"Nivolumab (anti-PD-1; BMS-936558, ONO-4538) in combination with sunitinib or pazopanib in patients (pts) with metastatic renal cell carcinoma (mRCC).","volume":"32","author":"Amin","year":"2014","journal-title":"J Clin Oncol"},{"issue":"5s","key":"10.1136\/esmoopen-2017-000165_bb0315","article-title":"Phase I study of nivolumab in combination with ipilimumab in metastatic renal cell carcinoma (mRCC)","volume":"32","author":"Hans","year":"2014","journal-title":"J Clin Oncol"},{"issue":"suppl; abstr TPS4578","key":"10.1136\/esmoopen-2017-000165_bb0320","article-title":"CheckMate 214: a phase III, randomized, open-label study of nivolumab combined with ipilimumab versus sunitinib monotherapy in patients with previously untreated metastatic renal cell carcinoma","volume":"33","author":"Hans","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1136\/esmoopen-2017-000165_bb0325","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1158\/0008-5472.CAN-08-3529","article-title":"Potentiating endogenous antitumor immunity to prostate cancer through combination immunotherapy with CTLA4 blockade and GM-CSF","volume":"69","author":"Fong","year":"2009","journal-title":"Cancer Res"},{"key":"10.1136\/esmoopen-2017-000165_bb0330","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1158\/1078-0432.CCR-06-2318","article-title":"A pilot trial of CTLA-4 blockade with human anti-CTLA-4 in patients with hormone-refractory prostate Cancer","volume":"13","author":"Small","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1136\/esmoopen-2017-000165_bb0335","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1093\/annonc\/mdt107","article-title":"Ipilimumab alone or in combination with radiotherapy in metastatic castration-resistant prostate cancer: results from an open-label, multicenter phase I\/II study","volume":"24","author":"Slovin","year":"2013","journal-title":"Ann Oncol"},{"key":"10.1136\/esmoopen-2017-000165_bb0340","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1016\/S1470-2045(14)70189-5","article-title":"Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial","volume":"15","author":"Kwon","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1136\/esmoopen-2017-000165_bb0345","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1007\/s00262-011-1193-1","article-title":"Phase I trial of tremelimumab in combination with short-term androgen deprivation in patients with PSA-recurrent prostate cancer","volume":"61","author":"McNeel","year":"2012","journal-title":"Cancer Immunology, Immunotherapy"},{"issue":"suppl_6","key":"10.1136\/esmoopen-2017-000165_bb0350","article-title":"First evidence of significant clinical activity of PD-1 inhibitors in metastatic, castration resistant prostate cancer (mCRPC)","volume":"27","author":"Graff","year":"2016","journal-title":"Annals of Oncology"},{"key":"10.1136\/esmoopen-2017-000165_bb0355","doi-asserted-by":"crossref","first-page":"32455","DOI":"10.1016\/S0140-6736(16)32455-2","article-title":"Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial","volume":"389","author":"Balar","year":"2017","journal-title":"Lancet"},{"key":"10.1136\/esmoopen-2017-000165_bb0360","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1016\/S1470-2045(16)30496-X","article-title":"Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): a multicentre, open-label, two-stage, multi-arm, phase 1\/2 trial","volume":"17","author":"Sharma","year":"2016","journal-title":"Lancet Oncol"}],"container-title":["ESMO Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702920324492?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702920324492?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/esmoopen-2017-000165","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T20:20:22Z","timestamp":1761855622000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2059702920324492"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017]]},"references-count":71,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2017]]}},"alternative-id":["S2059702920324492"],"URL":"https:\/\/doi.org\/10.1136\/esmoopen-2017-000165","relation":{},"ISSN":["2059-7029"],"issn-type":[{"value":"2059-7029","type":"print"}],"subject":[],"published":{"date-parts":[[2017]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Checkpoint inhibitors in the treatment of urological malignancies","name":"articletitle","label":"Article Title"},{"value":"ESMO Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1136\/esmoopen-2017-000165","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 THE AUTHORS. Published by Elsevier Limited on behalf of European Society for Medical Oncology; Originally published by BMJ.","name":"copyright","label":"Copyright"}],"article-number":"e000165"}}